Citi Starts Forte Biosciences Inc. (FBRX) at Buy
- Wall Street rebounds after two-day decline; Netflix slides
- Netflix (NFLX) Plunges Following Q1 Sub Miss, But One Analyst Sees Chance to Turn Bullish
- Oil prices drop 2% on U.S. crude build, COVID-19 surge in India
- Intuitive Surgical (ISRG) Q1 Beat Prompts Two Street Upgrades
- U.S. dollar losses bounce after Canada tips toward higher rates
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Citi analyst Mohit Bansal initiates coverage on Forte Biosciences Inc. (NASDAQ: FBRX) with a Buy rating and a price target of $75.00.
The analyst comments "We are initiating coverage of Forte (FBRX) with a Buy (High-Risk) as we think FB-401, the company’s lead asset is a relatively de-risked asset which can become standard of care among mild adult atopic dermatitis (AD) and pediatric AD. Robust data from FB-401’s Ph 1/2 trial with ~90% pts responding on EASI-50 endpoint de-risks upcoming Ph2 data in 3Q21, which has a significantly lower bar for success. Success would push the company closer to its $2B unadj. opportunity ($1B in base case) and we see the stock trading between $75-$107/sh (+180%-300% from current levels) assuming 50-65% probability upon success. Ph 2 success could also make Forte an M&A target as we see M&A value at $205/sh (+650% from current levels)."
Shares of Forte Biosciences Inc. closed at $29.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Fennec Pharma (FENC) is Saving Pediatric Cancer Patients Hearing, Initiated with Buy at Craig-Hallum Ahead of Major Catalyst
- BHP (BHP:LN) (BHP) PT Raised to GBP25.20 at Goldman Sachs
- UPDATE: Oppenheimer Starts Gladstone Investment Corporation (GAIN) at Perform
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Hot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!